DK0835305T3 - Cytokin som inducerer apoptose - Google Patents

Cytokin som inducerer apoptose

Info

Publication number
DK0835305T3
DK0835305T3 DK96922583T DK96922583T DK0835305T3 DK 0835305 T3 DK0835305 T3 DK 0835305T3 DK 96922583 T DK96922583 T DK 96922583T DK 96922583 T DK96922583 T DK 96922583T DK 0835305 T3 DK0835305 T3 DK 0835305T3
Authority
DK
Denmark
Prior art keywords
trail
induces apoptosis
cells
cytokine
antibodies
Prior art date
Application number
DK96922583T
Other languages
Danish (da)
English (en)
Inventor
Raymond G Goodwin
Steven R Wiley
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27052201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0835305(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0835305T3 publication Critical patent/DK0835305T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L27/00—Modulated-carrier systems
    • H04L27/18—Phase-modulated carrier systems, i.e. using phase-shift keying
    • H04L27/22—Demodulator circuits; Receiver circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96922583T 1995-06-29 1996-06-25 Cytokin som inducerer apoptose DK0835305T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49663295A 1995-06-29 1995-06-29
US54836895A 1995-11-01 1995-11-01

Publications (1)

Publication Number Publication Date
DK0835305T3 true DK0835305T3 (da) 2006-02-13

Family

ID=27052201

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05077545.1T DK1666591T3 (da) 1995-06-29 1996-06-25 Cytokin der inducerer apoptose
DK96922583T DK0835305T3 (da) 1995-06-29 1996-06-25 Cytokin som inducerer apoptose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05077545.1T DK1666591T3 (da) 1995-06-29 1996-06-25 Cytokin der inducerer apoptose

Country Status (16)

Country Link
US (1) US5763223A (xx)
EP (2) EP1666591B1 (xx)
JP (1) JP4435304B2 (xx)
KR (2) KR101004174B1 (xx)
AT (2) ATE310813T1 (xx)
AU (1) AU708239B2 (xx)
CA (1) CA2225378C (xx)
DE (2) DE69635480T2 (xx)
DK (2) DK1666591T3 (xx)
ES (2) ES2362191T3 (xx)
HK (2) HK1010215A1 (xx)
IL (6) IL122408A0 (xx)
NO (1) NO321707B1 (xx)
NZ (1) NZ311982A (xx)
PT (1) PT1666591E (xx)
WO (1) WO1997001633A1 (xx)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715645B2 (en) * 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20040048340A1 (en) * 1996-03-14 2004-03-11 Human Genome Sciences, Inc. Apoptosis inducing molecule I
WO1997046686A2 (en) * 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
EP0951551B9 (en) 1996-12-23 2012-12-26 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6342363B1 (en) * 1997-01-28 2002-01-29 Human Genome Sciences, Inc. Death domain containing receptor 4 nucleic acids and methods
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
JP3813682B2 (ja) * 1997-01-29 2006-08-23 小山 省三 ワクチン前駆体およびワクチン
US20020009467A1 (en) 1997-01-29 2002-01-24 Shozo Koyama Antigenic substance inductor, vaccine precursor, vaccine, antibody, neutralizing antibody, antitoxin, idiotype antibody and/or anti-idiotype antibody which is induced by its idiotype antibody
WO1998035061A2 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
AU747635B2 (en) * 1997-03-17 2002-05-16 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
CN1264427A (zh) * 1997-04-16 2000-08-23 安姆根有限公司 osteoprotegerin结合蛋白和受体
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
CA2287911C (en) * 1997-05-15 2014-05-06 Genentech, Inc. Apo-2 receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
JP2002508663A (ja) * 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Ａｐｏ−２ＤｃＲ
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
AU8400398A (en) * 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
FR2766713B1 (fr) * 1997-08-04 1999-09-24 Bio Merieux Facteur proteique associe a une maladie neuro-degenerative et/ou auto-immune et/ou inflammatoire
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
AU5201399A (en) * 1997-09-30 1999-10-18 Pharmacia & Upjohn Company Tnf-related death ligand
DK1032672T3 (da) * 1997-11-18 2009-04-27 Genentech Inc DNA19355-polypeptid, en tumornekrosefaktor-homolog
US7019119B2 (en) * 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
EP2017341A3 (en) * 1998-01-15 2009-04-08 Genentech, Inc. Apo-2 ligand
US20040180049A1 (en) * 1998-01-26 2004-09-16 Genentech, Inc. DR4 antibodies and uses thereof
US20040120947A1 (en) * 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
CA2324494A1 (en) * 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
EP1086138B1 (en) * 1998-06-12 2009-09-23 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
WO2000002584A2 (en) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1129102A1 (en) * 1998-11-02 2001-09-05 Clontech Laboratories Inc. Gene and protein for regulation of cell death
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US7465785B2 (en) * 1999-03-08 2008-12-16 Genentech, Inc. Polypeptide encoded by a nucleic acid over-expressed in melanoma
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
IL145676A0 (en) 1999-04-12 2002-06-30 Genentech Inc Tumor necrosis factor homologs and nucleic acids encoding the same
WO2000063253A1 (en) * 1999-04-16 2000-10-26 Amgen Inc. Agp-1 fusion protein compositions and methods
EP1867719A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
JP5118796B2 (ja) * 1999-06-28 2013-01-16 ジェネンテック， インコーポレイテッド 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
US6444640B1 (en) * 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof
EP1223961A4 (en) * 1999-09-30 2005-10-05 Univ Pennsylvania "TRAIL" AS INHIBITOR OF AUTOIMMUNE INFLAMMATION AND CELL CYCLE PROGRESSION
US6824773B2 (en) 1999-12-20 2004-11-30 Immunex Corporation TWEAK receptor
AU784614B2 (en) * 2000-01-24 2006-05-11 University Of Louisville Research Foundation, Inc. Immune modulation with death receptor-induced apoptosis
US7927602B2 (en) * 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
ATE511857T1 (de) 2000-02-16 2011-06-15 Genentech Inc Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US6900185B1 (en) 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
US7238360B2 (en) * 2000-06-30 2007-07-03 Unversity Of Louisville Research Foundation, Inc. Alteration of cell membrane with B7
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
ATE391174T1 (de) 2000-10-20 2008-04-15 Chugai Pharmaceutical Co Ltd Modifizierter tpo-agonisten antikörper
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
WO2002079377A2 (en) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20020155109A1 (en) * 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7064189B2 (en) 2001-05-25 2006-06-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
GB0113920D0 (en) 2001-06-07 2001-08-01 Sterix Ltd Composition
CN103232539B (zh) 2001-06-26 2015-06-03 安姆根弗里蒙特公司 抗opgl抗体
EP1409544B1 (en) 2001-07-03 2009-06-17 Genentech, Inc. Human dr4 antibodies and uses thereof
WO2003013555A1 (en) * 2001-08-08 2003-02-20 Board Of Regents, The University Of Texas System Method for amplifying expression from a cell specific promoter
JP2005508162A (ja) * 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
AU2007200478A1 (en) * 2001-11-13 2007-02-22 Genentech, Inc. APO2 ligand/trail formulations
ES2351786T3 (es) 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
CA2471140A1 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
MXPA04009681A (es) * 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
BR0312692A (pt) 2002-07-15 2007-06-26 Univ Texas anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer
WO2004052292A2 (en) * 2002-12-06 2004-06-24 University Of South Florida Histone deacetylase inhibitor enhancement of trail-induced apoptosis
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
JP2007505860A (ja) * 2003-09-18 2007-03-15 ノバルティス　アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤と細胞死受容体リガンドの組み合わせ
WO2005042744A1 (fr) * 2003-11-03 2005-05-12 Beijing Sunbio Biotech Co., Ltd. Proteine de recombinaison anticancereuse, ses genes codant et ses utilisations
JPWO2005056605A1 (ja) 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
MXPA06008293A (es) 2004-01-22 2007-06-11 Univ Miami Formulaciones topicas de coenzima q10 y metodos de uso.
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
US7294483B2 (en) 2004-03-11 2007-11-13 Genentech, Inc. Process for producing recombinant polypeptides via a glycerol phosphate or sugar phosphate feed
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
CA2575755C (en) 2004-08-06 2014-04-08 Genentech, Inc. Assays and methods using biomarkers
RU2431676C2 (ru) 2004-08-06 2011-10-20 Дженентек, Инк. Анализы и способы с применением биомаркеров
MX2007002855A (es) * 2004-09-08 2007-04-27 Genentech Inc Metodos para usar ligandos de receptor de muerte y anticuerpos cd20.
BRPI0515604A (pt) * 2004-09-08 2008-07-29 Genentech Inc método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
EP1645875A1 (en) * 2004-10-08 2006-04-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnosis and therapy of cell proliferative disorders characterized by resistance to TRAIL induced apoptosis
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060228352A1 (en) * 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
WO2006106903A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
ES2380119T3 (es) * 2005-08-16 2012-05-08 Genentech, Inc. Sensibilidad apoptótica a APO2L/TRAIL analizando la expresión de GalNac-T14 en células/tejidos
AU2006283174A1 (en) * 2005-08-24 2007-03-01 Cell-Matrix, Inc. Combination therapies for inhibiting integrin-extracellular matrix interactions
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
US20100047783A1 (en) * 2006-06-20 2010-02-25 El-Diery Wafik S Small molecule modulators of p53 family signaling
WO2008088582A2 (en) * 2006-08-04 2008-07-24 Mayo Foundation For Medical Education And Research Methods and materials related to trail isoforms
EP2136831B1 (en) 2007-03-02 2012-09-12 The Cleveland Clinic Foundation Anti-angiogenic peptides
CA2860950C (en) 2007-07-10 2017-08-01 Apogenix Gmbh Tnf superfamily collectin fusion proteins
AU2013203061B2 (en) * 2007-07-10 2016-07-28 Apogenix Ag TNF superfamily collectin fusion proteins
WO2009025743A2 (en) * 2007-08-17 2009-02-26 University Of Massachusetts Medical School Use of trail compositions as antiviral agents
CN101157729B (zh) * 2007-10-23 2011-01-12 南京大学 一种肿瘤坏死因子相关凋亡配体变体及其应用
JP5809415B2 (ja) 2007-11-09 2015-11-10 ペレグリン ファーマシューティカルズ，インコーポレーテッド 抗ｖｅｇｆ抗体の組成物および方法
KR20110089185A (ko) 2008-11-25 2011-08-04 바이오겐 아이덱 엠에이 인코포레이티드 신경계 세포의 생존을 촉진하기 위한 ｄｒ６ 및 ｐ７５ 길항제의 용도
ES2593049T3 (es) 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
ES2356880B8 (es) 2009-08-21 2012-10-30 Universidad De Zaragoza Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail.
CN102686606A (zh) * 2009-10-09 2012-09-19 阿纳福公司 结合il-23r的多肽
KR101380840B1 (ko) * 2010-04-01 2014-04-04 한국생명공학연구원 Ｔｒａｉｌ 센서타이저 타겟 유전자인 ｔｉｐ４１의 발현 또는 활성 억제제를 함유하는 ｔｒａｉｌ 감수성 증진용 조성물
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
US9012178B2 (en) 2010-08-05 2015-04-21 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
CA2814595C (en) 2010-12-03 2020-06-16 Adamed Sp. Z O.O. Anticancer fusion protein
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
IL310968A (en) 2011-07-01 2024-04-01 Amgen Inc Mammalian cell culture
CN102908612A (zh) * 2011-08-02 2013-02-06 北京诺赛基因组研究中心有限公司 TRAIL截短型变异体活化NF-κB和在炎症反应中的应用
WO2013033600A1 (en) 2011-09-02 2013-03-07 Amgen Inc. Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
EP2752429B1 (en) * 2011-09-16 2017-03-01 Beijing Sunbio Biotech Co. Ltd. Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
PL223487B1 (pl) 2011-12-28 2016-10-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
EP2931287B1 (de) * 2012-12-11 2017-10-04 Sapiotec GmbH Delphinidin zur bekämpfung von melanomzellen
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
ME02917B (me) 2013-03-14 2018-10-20 Bristol Myers Squibb Co Kombinacija dr5 agoniste i anti-pd--1 antagoniste i načini primjene
TWI720289B (zh) 2013-03-14 2021-03-01 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
DK2969099T4 (da) 2013-03-14 2022-03-14 Amgen Inc Fjernelse af lækket affinitetsoprensningsligand
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
CN103555729B (zh) * 2013-10-14 2016-08-24 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用
WO2015066357A1 (en) 2013-10-31 2015-05-07 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
SG10201806643WA (en) 2014-01-13 2018-09-27 Amgen Inc Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
CN113774084B (zh) 2014-01-29 2024-04-16 美国安进公司 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
KR102598799B1 (ko) 2014-06-04 2023-11-07 암젠 인크 포유류 세포 배양물을 회수하는 방법
AU2015349809B2 (en) 2014-11-19 2022-02-10 Amgen Inc. Quantitation of glycan moiety in recombinant glycoproteins
EP3680344A1 (en) 2014-12-01 2020-07-15 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
AU2016371021B2 (en) 2015-12-17 2020-04-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
CA3007419A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
CN116064677A (zh) * 2016-02-05 2023-05-05 斯比根公司 表达trail和cd的间充质干细胞及其用途
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
KR101739703B1 (ko) * 2016-09-13 2017-05-24 (주) 어드밴스드 엔티 Trail 기반 뇌염 감별진단 방법 및 장치
US11519007B2 (en) 2019-02-22 2022-12-06 Arizona Board Of Regents On Behalf Of Arizona State University Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy
WO2023129974A1 (en) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation of landing pad cell lines

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
EP0276846A3 (en) 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
CA2049028A1 (en) 1989-03-07 1990-09-08 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
WO1990013641A1 (en) 1989-05-10 1990-11-15 Sloan-Kettering Institute For Cancer Research Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
KR920702409A (ko) 1989-10-24 1992-09-04 원본미기재 새로운 결합을 갖는 올리고뉴클레오티드 유사체
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU678787B2 (en) 1992-10-23 1997-06-12 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5512435A (en) * 1993-02-05 1996-04-30 Renschler; Markus F. Receptor-binding antiproliferative peptides
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP0723556A4 (en) 1993-10-14 2003-03-19 Immunex Corp FAS ANTAGONISTS AND THEIR APPLICATIONS
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
WO1997033899A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997046686A2 (en) * 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide

Also Published As

Publication number Publication date
CA2225378C (en) 2012-04-17
WO1997001633A1 (en) 1997-01-16
IL184699A (en) 2011-11-30
AU6340796A (en) 1997-01-30
MX9710399A (es) 1998-03-31
EP0835305B1 (en) 2005-11-23
CA2225378A1 (en) 1997-01-16
EP0835305A4 (en) 2002-02-06
HK1010215A1 (en) 1999-06-17
EP0835305A1 (en) 1998-04-15
NO976045L (no) 1998-03-02
EP1666591A1 (en) 2006-06-07
DE69635480T2 (de) 2006-08-17
NZ311982A (en) 1999-08-30
IL149261A0 (en) 2002-11-10
IL149261A (en) 2006-09-05
IL190068A0 (en) 2008-08-07
DK1666591T3 (da) 2011-05-23
IL122408A0 (en) 1998-06-15
HK1092836A1 (en) 2007-02-16
KR19990028264A (ko) 1999-04-15
AU708239B2 (en) 1999-07-29
KR20050085914A (ko) 2005-08-29
US5763223A (en) 1998-06-09
PT1666591E (pt) 2011-06-01
IL184699A0 (en) 2007-12-03
EP1666591B1 (en) 2011-03-23
KR100510234B1 (ko) 2005-11-25
NO321707B1 (no) 2006-06-26
DE69638346D1 (de) 2011-05-05
ES2362191T3 (es) 2011-06-29
JP4435304B2 (ja) 2010-03-17
ATE310813T1 (de) 2005-12-15
ES2253753T3 (es) 2006-06-01
IL122408A (en) 2008-03-20
KR101004174B1 (ko) 2010-12-24
DE69635480D1 (de) 2005-12-29
ATE503013T1 (de) 2011-04-15
JPH11508445A (ja) 1999-07-27
NO976045D0 (no) 1997-12-22

Similar Documents

Publication Publication Date Title
DK0835305T3 (da) Cytokin som inducerer apoptose
FI961251A (fi) Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet
ATE341627T1 (de) Als lerk6 bezeichnetes cytokin
DK0871702T3 (da) Cytokin betegnet Lerk-7
DK0757717T3 (da) Papillomavirusvacciner
DK0574512T3 (da) Omdirigering af cellulær immunitet med receptorkimærer
DK0663010T3 (da) Fremgangsmåde til forøgelse af sekretion af overudtrykte proteiner
ATE386101T1 (de) Expressionsplasmide, durch einen osmb promoter reguliert
NO992916L (no) Fosfodiesterase 8A
ES545725A0 (es) Procedimiento para preparar peptidos de interferon
CO5290297A1 (es) Factor activador de la citoquina altamente purificado y metodos de su uso
DE68918712T2 (de) Rekombinante Eimeria tenella-Vakzine.
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
NO971378L (no) Cytokin betegnet LERK-6
NO984233L (no) Cytokin kalt lerk-8
IT8822682A0 (it) Conglomerato cementizio, particolarmente per mattonelle del tipo detto marmetta.